The invention provides a transdermal patch that has sufficient adhesiveness but causes little skin irritation when applied to the skin, has good cutaneous permeability by risperidone or a salt thereof, and shows sufficient percutaneous absorption. Specifically, by means of a transdermal patch wherein an adhesive layer supporting a drug is formed on a substrate, the adhesive layer comprises a thermoplastic elastomer, a liquid component in an amount that exceeds 300 parts by weight per 100 parts b...

Provided is a skin irritation suppressant for transdermal preparations, having a sufficient reduction effect of skin irritation due to a drug. Also provided is a transdermal preparation comprising the skin irritation suppressant. One embodiment of the invention is a skin irritation suppressant for suppressing the skin irritation due to a drug and a pharmaceutical ingredient to be used in a transdermal preparation other than the drug, the skin irritation suppressant comprising a sterol compound s...

The present invention relates to a one-step process for the preparation of the antipsychotic agent Paliperidone by oxidation of Risperidone and to Paliperidone oxalate or a hydrate solvate or polymorph thereof.

The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer m...

The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer m...

Disclosed is the use of a dopamine receptor D2 inhibitor medicament for treating depression improving cognition and/or treating other syndromes conditions or diseases for which anti-depressant agents are prescribed. The dopamine receptor D2 inhibitor medicament is formulated for administration in an administration cycle the administration cycle comprising: i. administering the D2 receptor inhibitor to elevate amounts of the D2 receptor's high affinity state inducing dopamine receptor supersensit...